Marketed in 31 countries across much of the European regulatory area, Hemangiol is a brand of propranolol, classified among the beta-blocking agents and used clinically as an antihypertensive, antianginal, and antiarrhythmic. Propranolol is one of the oldest and most internationally familiar molecules in its class, and a traveller or expatriate carrying Hemangiol is carrying a medication whose active ingredient is recognised by pharmacists almost everywhere in the world, even if the specific brand name is not.
Propranolol is prescribed across a notably broad range of indications. The registered uses associated with Hemangiol include hypertension, angina pectoris, certain arrhythmias such as ventricular tachycardia and atrial flutter, tachycardia more generally, aspects of heart disease, complications associated with cirrhosis, and seizure prophylaxis in defined clinical contexts. The structured indication list further down this page details the uses recognised across the markets where Hemangiol is authorised.
Hemangiol's footprint is heavily European — examples of registered markets include France, Germany, Italy, Ireland, and Iceland, along with much of Central and Eastern Europe. Outside this cluster, propranolol itself is essentially universal, but the brand on the box is likely to be different. Regulatory packaging, available strengths, and prescription pathways vary considerably from one country to another, and a pharmacist in the destination country can confirm whether a locally available propranolol product is the appropriate substitute.
Other medications in the beta-blocker class are sold worldwide under different molecules and brand names, although they are not freely interchangeable with propranolol. Anyone taking Hemangiol, considering it, or attempting to identify a local equivalent should treat substitution as a clinical decision made together with a healthcare provider familiar with their history.
Hemangiol is prescribed within the cardiovascular and related therapeutic areas covered by propranolol, including hypertension, angina pectoris, certain arrhythmias such as ventricular tachycardia and atrial flutter, tachycardia, aspects of heart disease, complications of cirrhosis, and seizure prophylaxis in defined clinical situations. The structured indication block on this page lists the registered uses recognised in the markets where Hemangiol is authorised.
Hemangiol contains propranolol, classified among the beta-blocking agents and used as an antihypertensive, antianginal, and antiarrhythmic. Propranolol is one of the longest-established molecules in this category and circulates internationally under a number of different brand names — the same active ingredient is what defines the therapeutic role rather than any one commercial label.
Hemangiol is registered in 31 countries, with a footprint concentrated across the European regulatory area. Representative markets include France, Germany, Italy, Ireland, Greece, Iceland, and the Czech Republic. If your country is not on the list shown on this page, a local pharmacist can usually confirm whether propranolol is available in that market under a different brand name or as a generic.
Propranolol is sold under several brand names worldwide, particularly as generic products in markets where the original patent has long since expired. Other medications within the broader beta-blocker class also exist, although molecules within the class differ in selectivity and clinical positioning and are not interchangeable without medical guidance. To identify a local propranolol-containing product, search the active ingredient on Pill2Trip or ask a pharmacist.
Yes. Hemangiol is a prescription medication, and beta-blocker therapy is calibrated to the individual patient's cardiovascular status, concurrent medications, and the specific indication being treated. This matters particularly for travellers and people relocating between countries, since prescription requirements, available formulations, and brand names differ between regulatory regimes. Any decision to start, stop, switch, or substitute propranolol should involve a healthcare provider who knows the patient's history.
